Welcome to our dedicated page for Firefly Neuroscience SEC filings (Ticker: AIFF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching a 300-page 10-K for details on Firefly Neuroscience’s FDA-cleared Brain Network Analytics platform can feel overwhelming. Investors typically want to confirm R&D spending on EEG diagnostics, check clinical-trial 8-K updates, and monitor Form 4 insider buys around neurology milestones—all without sifting through medical jargon.
Stock Titan’s AI reads every Firefly Neuroscience SEC document the moment it hits EDGAR and delivers plain-English explanations. Need the latest Firefly Neuroscience quarterly earnings report 10-Q filing? Our dashboard highlights revenue from BNA licensing and cash burn trends. Curious about Firefly Neuroscience insider trading Form 4 transactions? Real-time alerts flag when executives accumulate shares, so you can spot confidence signals fast. Even the proxy statement on executive compensation is distilled, showing how option grants align with brain-health milestones.
Whether you’re comparing segments in the annual report 10-K simplified, tracking Firefly Neuroscience executive stock transactions Form 4, or looking for a sudden partnership disclosed in an 8-K material events explained, our platform answers natural questions like “understanding Firefly Neuroscience SEC documents with AI” or “where to find Firefly Neuroscience earnings report filing analysis.” Comprehensive coverage, AI-powered summaries, and search-ready tagging mean every disclosure—from real-time Form 4 insider transactions to upcoming proxy votes—is one click away and easy to grasp.
Firefly Neuroscience, Inc. has issued a preliminary proxy for its virtual 2025 Annual Meeting to be held October 31, 2025. The Board recommends five proposals: elect two Class II directors to three-year terms ending 2028; ratify Marcum as independent auditor for fiscal 2025; approve Amendment No. 1 to the equity incentive plan to add 317,820 shares and provide annual automatic increases (up to 4% of outstanding shares) from January 1, 2026 through January 1, 2035; authorize the Board to increase authorized shares from 101,000,000 to up to 5,001,000,000 (including 1,000,000 preferred); and permit adjournment if needed to solicit votes. The proxy discloses board composition, committee charters, related-person transaction review procedures, indemnification and insurance, and executive compensation summary including pay-versus-performance tables and narrative. Proxy materials and the 2024 Form 10-K are available at the links provided.
FAQ
What is the current stock price of Firefly Neuroscience (AIFF)?
What is the market cap of Firefly Neuroscience (AIFF)?
